222 related articles for article (PubMed ID: 28415953)
1. Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis.
Maciejewska-Paszek I; Grochowska-Niedworok E; Siwiec A; Gruenpeter A; Dul L; Irzyniec T
J Int Med Res; 2017 Apr; 45(2):525-532. PubMed ID: 28415953
[TBL] [Abstract][Full Text] [Related]
2. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
Nimmrich S; Horneff G
Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
[TBL] [Abstract][Full Text] [Related]
3. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
[TBL] [Abstract][Full Text] [Related]
4. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
[TBL] [Abstract][Full Text] [Related]
5. Etanercept treatment for children with refractory juvenile idiopathic arthritis.
Kuo HC; Yu HR; Wu CC; Chang LS; Yang KD
J Microbiol Immunol Infect; 2011 Feb; 44(1):52-6. PubMed ID: 21531353
[TBL] [Abstract][Full Text] [Related]
6. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
Verazza S; Davì S; Consolaro A; Bovis F; Insalaco A; Magni-Manzoni S; Nicolai R; Marafon DP; De Benedetti F; Gerloni V; Pontikaki I; Rovelli F; Cimaz R; Marino A; Zulian F; Martini G; Pastore S; Sandrin C; Corona F; Torcoletti M; Conti G; Fede C; Barone P; Cattalini M; Cortis E; Breda L; Olivieri AN; Civino A; Podda R; Rigante D; La Torre F; D'Angelo G; Jorini M; Gallizzi R; Maggio MC; Consolini R; De Fanti A; Muratore V; Alpigiani MG; Ruperto N; Martini A; Ravelli A;
Pediatr Rheumatol Online J; 2016 Dec; 14(1):68. PubMed ID: 27993144
[TBL] [Abstract][Full Text] [Related]
7. 90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis.
Cecamore C; Marsili M; Salvatore R; Troiani R; D'Egidio M; Tinari N; Pelliccia P; Chiarelli F; Marcovecchio ML; Breda L
Mod Rheumatol; 2018 Jul; 28(4):637-641. PubMed ID: 29157059
[TBL] [Abstract][Full Text] [Related]
8. Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept.
Öman A; Dicksved J; Engstrand L; Berntson L
Pediatr Rheumatol Online J; 2021 Apr; 19(1):55. PubMed ID: 33902613
[TBL] [Abstract][Full Text] [Related]
9. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan.
Hsin YC; Zhuang LZ; Yeh KW; Chang CW; Horng JT; Huang JL
PLoS One; 2015; 10(6):e0128768. PubMed ID: 26047099
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
Davies R; Gaynor D; Hyrich KL; Pain CE
Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
[TBL] [Abstract][Full Text] [Related]
12. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
Su Y; Yang YH; Chiang BL
Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate.
Alexeeva E; Dvoryakovskaya T; Denisova R; Sleptsova T; Isaeva K; Chomahidze A; Fetisova A; Mamutova A; Alshevskaya A; Gladkikh V; Moskalev A
Pediatr Neonatol; 2019 Oct; 60(5):549-555. PubMed ID: 30885783
[TBL] [Abstract][Full Text] [Related]
14. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
[TBL] [Abstract][Full Text] [Related]
15. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
16. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
[TBL] [Abstract][Full Text] [Related]
17. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.
Kahn R; Berthold E; Gullstrand B; Schmidt T; Kahn F; Geborek P; Saxne T; Bengtsson AA; Månsson B
Acta Paediatr; 2016 Apr; 105(4):427-32. PubMed ID: 26707699
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
[TBL] [Abstract][Full Text] [Related]
19. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
